{"id":1470,"date":"2020-02-09T16:20:32","date_gmt":"2020-02-09T15:20:32","guid":{"rendered":"http:\/\/invivo.partners\/?post_type=portoflio_invivo&#038;p=1470"},"modified":"2025-01-16T09:20:04","modified_gmt":"2025-01-16T08:20:04","slug":"telum-therapeutics-2","status":"publish","type":"portoflio_invivo","link":"https:\/\/invivo.partners\/es\/portoflio_invivo\/telum-therapeutics-2\/","title":{"rendered":"Telum Therapeutics"},"content":{"rendered":"\r\n<p class=\"wp-block-paragraph\">Telum Therapeutics es una empresa de biolog\u00eda sint\u00e9tica que desarrolla nuevos tratamientos para las <strong>infecciones MDR<\/strong> causadas por bacterias <strong>Gram negativas<\/strong>, basados en el uso de enzimas l\u00edticas de los bacteri\u00f3fagos, llamados <strong>enzibi\u00f3ticos<\/strong>. La empresa ha desarrollado la <strong>plataforma APEX\u2122\ufe0f<\/strong>: <em>Advanced Phage-derived Enzybiotics from eXploration<\/em>, que permite el descubrimiento de nuevos enzibi\u00f3ticos e ingenier\u00eda para crear enzimas l\u00edticas quim\u00e9ricas.<\/p>\r\n\r\n\r\n\r\n<ul class=\"wp-block-list\">\r\n<li>CEO y cofundador: Roberto D\u00edez<\/li>\r\n<li>CFO y cofundador: Rub\u00e9n D\u00edez<\/li>\r\n<li>CSO: Chad Euler<\/li>\r\n<li>Ubicaci\u00f3n: No\u00e1in (Navarra)<\/li>\r\n<li>P\u00e1gina web: <a href=\"https:\/\/telumtherapeutics.com\/\" target=\"_blank\" rel=\"noreferrer noopener\">telumtherapeutics.com<\/a><\/li>\r\n<\/ul>\r\n\r\n\r\n\r\n<p class=\"wp-block-paragraph\">&nbsp;<\/p>\r\n","protected":false},"featured_media":0,"template":"","tipo_portfolio":[507],"class_list":["post-1470","portoflio_invivo","type-portoflio_invivo","status-publish","hentry","tipo_portfolio-invivoventures"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v21.3 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Telum Therapeutics - Invivo Partners<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/invivo.partners\/es\/portoflio_invivo\/telum-therapeutics-2\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Telum Therapeutics - Invivo Partners\" \/>\n<meta property=\"og:description\" content=\"Telum Therapeutics es una empresa de biolog\u00eda sint\u00e9tica que desarrolla nuevos tratamientos para las infecciones MDR causadas por bacterias Gram negativas, basados en el uso de enzimas l\u00edticas de los bacteri\u00f3fagos, llamados enzibi\u00f3ticos. La empresa ha desarrollado la plataforma APEX\u2122\ufe0f: Advanced Phage-derived Enzybiotics from eXploration, que permite el descubrimiento de nuevos enzibi\u00f3ticos e ingenier\u00eda para\" \/>\n<meta property=\"og:url\" content=\"https:\/\/invivo.partners\/es\/portoflio_invivo\/telum-therapeutics-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Invivo Partners\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-16T08:20:04+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minuto\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/invivo.partners\/es\/portoflio_invivo\/telum-therapeutics-2\/\",\"url\":\"https:\/\/invivo.partners\/es\/portoflio_invivo\/telum-therapeutics-2\/\",\"name\":\"Telum Therapeutics - Invivo Partners\",\"isPartOf\":{\"@id\":\"https:\/\/invivo.partners\/#website\"},\"datePublished\":\"2020-02-09T15:20:32+00:00\",\"dateModified\":\"2025-01-16T08:20:04+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/invivo.partners\/es\/portoflio_invivo\/telum-therapeutics-2\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/invivo.partners\/es\/portoflio_invivo\/telum-therapeutics-2\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/invivo.partners\/es\/portoflio_invivo\/telum-therapeutics-2\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\/\/invivo.partners\/es\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Telum Therapeutics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/invivo.partners\/#website\",\"url\":\"https:\/\/invivo.partners\/\",\"name\":\"Invivo Capital\",\"description\":\"Somos un fondo de capital riesgo especializado en proyectos early-stage del sector salud.\",\"publisher\":{\"@id\":\"https:\/\/invivo.partners\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/invivo.partners\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/invivo.partners\/#organization\",\"name\":\"Invivo Capital\",\"url\":\"https:\/\/invivo.partners\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/invivo.partners\/#\/schema\/logo\/image\/\",\"url\":\"http:\/\/invivo.partners\/wp-content\/uploads\/2020\/04\/InvivoCapital_Banner.jpg\",\"contentUrl\":\"http:\/\/invivo.partners\/wp-content\/uploads\/2020\/04\/InvivoCapital_Banner.jpg\",\"width\":1200,\"height\":630,\"caption\":\"Invivo Capital\"},\"image\":{\"@id\":\"https:\/\/invivo.partners\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Telum Therapeutics - Invivo Partners","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/invivo.partners\/es\/portoflio_invivo\/telum-therapeutics-2\/","og_locale":"es_ES","og_type":"article","og_title":"Telum Therapeutics - Invivo Partners","og_description":"Telum Therapeutics es una empresa de biolog\u00eda sint\u00e9tica que desarrolla nuevos tratamientos para las infecciones MDR causadas por bacterias Gram negativas, basados en el uso de enzimas l\u00edticas de los bacteri\u00f3fagos, llamados enzibi\u00f3ticos. La empresa ha desarrollado la plataforma APEX\u2122\ufe0f: Advanced Phage-derived Enzybiotics from eXploration, que permite el descubrimiento de nuevos enzibi\u00f3ticos e ingenier\u00eda para","og_url":"https:\/\/invivo.partners\/es\/portoflio_invivo\/telum-therapeutics-2\/","og_site_name":"Invivo Partners","article_modified_time":"2025-01-16T08:20:04+00:00","twitter_card":"summary_large_image","twitter_misc":{"Tiempo de lectura":"1 minuto"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/invivo.partners\/es\/portoflio_invivo\/telum-therapeutics-2\/","url":"https:\/\/invivo.partners\/es\/portoflio_invivo\/telum-therapeutics-2\/","name":"Telum Therapeutics - Invivo Partners","isPartOf":{"@id":"https:\/\/invivo.partners\/#website"},"datePublished":"2020-02-09T15:20:32+00:00","dateModified":"2025-01-16T08:20:04+00:00","breadcrumb":{"@id":"https:\/\/invivo.partners\/es\/portoflio_invivo\/telum-therapeutics-2\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/invivo.partners\/es\/portoflio_invivo\/telum-therapeutics-2\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/invivo.partners\/es\/portoflio_invivo\/telum-therapeutics-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/invivo.partners\/es\/"},{"@type":"ListItem","position":2,"name":"Telum Therapeutics"}]},{"@type":"WebSite","@id":"https:\/\/invivo.partners\/#website","url":"https:\/\/invivo.partners\/","name":"Invivo Capital","description":"Somos un fondo de capital riesgo especializado en proyectos early-stage del sector salud.","publisher":{"@id":"https:\/\/invivo.partners\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/invivo.partners\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/invivo.partners\/#organization","name":"Invivo Capital","url":"https:\/\/invivo.partners\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/invivo.partners\/#\/schema\/logo\/image\/","url":"http:\/\/invivo.partners\/wp-content\/uploads\/2020\/04\/InvivoCapital_Banner.jpg","contentUrl":"http:\/\/invivo.partners\/wp-content\/uploads\/2020\/04\/InvivoCapital_Banner.jpg","width":1200,"height":630,"caption":"Invivo Capital"},"image":{"@id":"https:\/\/invivo.partners\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/invivo.partners\/es\/wp-json\/wp\/v2\/portoflio_invivo\/1470","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/invivo.partners\/es\/wp-json\/wp\/v2\/portoflio_invivo"}],"about":[{"href":"https:\/\/invivo.partners\/es\/wp-json\/wp\/v2\/types\/portoflio_invivo"}],"wp:attachment":[{"href":"https:\/\/invivo.partners\/es\/wp-json\/wp\/v2\/media?parent=1470"}],"wp:term":[{"taxonomy":"tipo_portfolio","embeddable":true,"href":"https:\/\/invivo.partners\/es\/wp-json\/wp\/v2\/tipo_portfolio?post=1470"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}